A phase 3, multicenter, randomized, open-label trial of trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)-MedSci.cn

A phase 3, multicenter, randomized, open-label trial of trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)

Zaman, K; Modi, S; Ohtan, S; Lee, C; Wang, Y; Saxena, K; Cameron, DA

SWISS MEDICAL WEEKLY, 2020; (): 28S

科室
- - 订阅+
  - 更多科室
工具
服务